Unicycive Therapeutics Averts Nasdaq Delisting Concerns
Company Announcements

Unicycive Therapeutics Averts Nasdaq Delisting Concerns

Unicycive Therapeutics (UNCY) has released an update.

Unicycive Therapeutics, Inc. faced delisting from the Nasdaq Capital Market after its stock value and bid price fell below Nasdaq’s minimum requirements. However, the company has successfully regained compliance with both the minimum market value and bid price standards, ensuring its continued listing on the exchange. This turnaround may capture the interest of stock market enthusiasts and investors monitoring company performance.

For further insights into UNCY stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyUnicycive Therapeutics reports Q3 EPS (13c), consensus (15c)
TheFlyUnicycive Therapeutics expects cash to fund operations into 2026
TheFlyUnicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App